{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T22:52:33Z","timestamp":1784328753021,"version":"3.55.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,3,24]],"date-time":"2016-03-24T00:00:00Z","timestamp":1458777600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"AristoPharma, Bangladesh"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Heart Journal"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.ihj.2016.03.021","type":"journal-article","created":{"date-parts":[[2016,4,13]],"date-time":"2016-04-13T20:38:07Z","timestamp":1460579887000},"page":"809-815","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Effects of sustained-release trimetazidine on chronically dysfunctional myocardium of ischemic dilated cardiomyopathy \u2013 Six months follow-up result"],"prefix":"10.1016","volume":"68","author":[{"given":"A.","family":"Momen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.K.","family":"Karmakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.Z.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Haque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.R.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.I.","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.S.","family":"Hossain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.M.","family":"Huda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3486-0757","authenticated-orcid":false,"given":"M.N.","family":"Goni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ihj.2016.03.021_bib0180","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1023\/A:1009884820941","article-title":"Incidence and epidemiology of heart failure","volume":"5","author":"Kannel","year":"2000","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.ihj.2016.03.021_bib0185","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1161\/CIRCULATIONAHA.105.542894","article-title":"Epidemiology and etiology of cardiomyopathy in Africa","volume":"112","author":"Sliwa","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2016.03.021_bib0190","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S1388-9842(00)00141-0","article-title":"More \u2018malignant\u2019 than cancer? Five-year survival following a first admission for heart failure","volume":"3","author":"Stewart","year":"2001","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ihj.2016.03.021_bib0195","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2217\/fca.09.26","article-title":"Trimetazidine: the future of cardiac function. Editorial","volume":"5","author":"Di Napoli","year":"2009","journal-title":"Future Cardiol"},{"key":"10.1016\/j.ihj.2016.03.021_bib0200","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1177\/107424840400900105","article-title":"Efficacy and safety of a metabolic modulator drug in chronic stable angina: review of evidence from clinical trials","volume":"9","author":"Chaitman","year":"2004","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.ihj.2016.03.021_bib0205","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/oxfordjournals.eurheartj.a059685","article-title":"Therapeutic value of a cardioprotective agent in patients with severe ischemic cardiomyopathy","volume":"11","author":"Brottier","year":"1990","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ihj.2016.03.021_bib0210","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S0002-9149(98)00500-1","article-title":"Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease: a double-blind, placebo-controlled, crossover study","volume":"82","author":"Lu","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ihj.2016.03.021_bib0215","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1016\/S0002-8703(03)00415-0","article-title":"A short and long term beneficial effects of partial free fatty acid inhibition in diabetic patients with ischemic dilated cardiomyopathy","volume":"146","author":"Fragasso","year":"2003","journal-title":"Am Heart J"},{"key":"10.1016\/j.ihj.2016.03.021_bib0220","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1016\/j.ehj.2004.06.034","article-title":"Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease","volume":"25","author":"Vitale","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ihj.2016.03.021_bib0225","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1136\/hrt.2003.031310","article-title":"Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy","volume":"91","author":"Di Napoli","year":"2005","journal-title":"Heart"},{"key":"10.1016\/j.ihj.2016.03.021_bib0230","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/01.RES.86.5.580","article-title":"The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A tiolase","volume":"86","author":"Kantor","year":"2000","journal-title":"Circ Res"},{"key":"10.1016\/j.ihj.2016.03.021_bib0235","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1053\/euhj.2001.2653","article-title":"Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy","volume":"22","author":"Belardinelli","year":"2001","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ihj.2016.03.021_bib0240","first-page":"97","article-title":"Anti-ischemia effects of trimetazidine: 31P-NMR spectroscopy in the isolated rat heart","volume":"286","author":"Lavanchy","year":"1987","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"10.1016\/j.ihj.2016.03.021_bib0245","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/j.1476-5381.1996.tb15268.x","article-title":"Effects of trimetazidine on pHi in the rat isolated ventricular myocyte","volume":"117","author":"Lagadic-Gossmann","year":"1996","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ihj.2016.03.021_bib0250","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/BF02125756","article-title":"Internal pH, Na+, and Ca+ regulation by trimetazidine during cardiac cell acidosis","volume":"1","author":"Renaud","year":"1988","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.ihj.2016.03.021_bib0255","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1365-2125.1985.tb05047.x","article-title":"Effects of trimetazidine on membrane damage induced by oxygen free radicals in human red cells","volume":"20","author":"Maridonneau-Parini","year":"1985","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ihj.2016.03.021_bib0260","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1006\/jmcc.1994.1116","article-title":"Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation","volume":"26","author":"Fantini","year":"1994","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.ihj.2016.03.021_bib0265","first-page":"1612","article-title":"Trimetazidine improves endothelial dysfunction in chronic heart failure: an antioxidant effect?","volume":"104","author":"Belardinelli","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2016.03.021_bib0270","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0891-5849(01)00537-8","article-title":"Trimetazidine protects low-density lipoproteins from oxidation and cultured cells exposed to H2O2 from DNA damage","volume":"30","author":"Tselepis","year":"2001","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.ihj.2016.03.021_bib0275","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1475-2840-2-16","article-title":"Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study","volume":"2","author":"Rosano","year":"2003","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ihj.2016.03.021_bib0280","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1093\/eurheartj\/ehi816","article-title":"Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatinine\/adenosine triphosphate ratio in patients with heart failure","volume":"27","author":"Fragasso","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ihj.2016.03.021_bib0285","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/FJC.0b013e31814fa9cb","article-title":"Trimetazidine and reduction in mortality and hospitalization in patients with ischemic dilated cardiomyopathy: a post hoc analysis of the Villa Pini D\u2019Abruzzo trimetazidine trial","volume":"50","author":"Di Napoli","year":"2007","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.ihj.2016.03.021_bib0290","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2165\/00129784-200505040-00006","article-title":"Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy","volume":"5","author":"El-Kady","year":"2006","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.ihj.2016.03.021_bib0295","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2165\/11316840-000000000-00000","article-title":"Effect of antianginal drugs in stable angina on predicted mortality risk after surviving a myocardial infarction","volume":"9","author":"Iyengar","year":"2009","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.ihj.2016.03.021_bib0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2840-2-16","article-title":"Trimetazidine improves left function in diabetic patients with coronary artery disease. A double-blind, placebo-controlled, study","volume":"2","author":"Rosano","year":"2003","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ihj.2016.03.021_bib0305","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/HJR.0b013e328304feec","article-title":"Trimetazidine potentiates the effects of exercise training in patients with ischemic cardiomyopathy referred for cardiac rehabilitation","volume":"15","author":"Belardinelli","year":"2008","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"10.1016\/j.ihj.2016.03.021_bib0310","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/oxfordjournals.eurheartj.a059685","article-title":"Therapeutic value of a cardioprotective agent in patients with severe ischemic cardiomyopathy","volume":"11","author":"Brottier","year":"1990","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ihj.2016.03.021_bib0315","doi-asserted-by":"crossref","first-page":"E18","DOI":"10.1016\/S0002-8703(03)00415-0","article-title":"Short and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy","volume":"146","author":"Fragasso","year":"2003","journal-title":"Am Heart J"},{"key":"10.1016\/j.ihj.2016.03.021_bib0320","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s12325-009-0024-7","article-title":"Effect of trimetazidine on quality of life in elderly patients with ischemic dilated cardiomyopathy","volume":"26","author":"Marazzi","year":"2009","journal-title":"Adv Ther"},{"key":"10.1016\/j.ihj.2016.03.021_bib0325","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jacc.2006.03.060","article-title":"A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure","volume":"48","author":"Fragasso","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ihj.2016.03.021_bib0330","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1161\/CIRCULATIONAHA.108.778019","article-title":"Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy","volume":"118","author":"Tuunanen","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2016.03.021_bib0335","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.ehj.2004.02.018","article-title":"Metabolic manipulation in ischemic heart disease, a novel approach to treatment","volume":"25","author":"Lee","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ihj.2016.03.021_bib0340","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1023\/A:1007731219206","article-title":"Effects of trimetazidine on metabolic and functional recovery of postischemic rat heart","volume":"12","author":"Allibardi","year":"1998","journal-title":"Cardiovasc Drug Ther"},{"key":"10.1016\/j.ihj.2016.03.021_bib0345","article-title":"Metabolic derangement in ischemic heart disease and its therapeutic control","volume":"82","author":"Ferrari","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ihj.2016.03.021_bib0350","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1159\/000139070","article-title":"Effect of trimetazidine on mitochondrial function and oxidative damage during reperfusion of ischemic hypertrophied myocardium","volume":"46","author":"Guarnieri","year":"1993","journal-title":"Pharmacology"}],"container-title":["Indian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001948321600122X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001948321600122X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T03:48:44Z","timestamp":1758080924000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001948321600122X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S001948321600122X"],"URL":"https:\/\/doi.org\/10.1016\/j.ihj.2016.03.021","relation":{},"ISSN":["0019-4832"],"issn-type":[{"value":"0019-4832","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of sustained-release trimetazidine on chronically dysfunctional myocardium of ischemic dilated cardiomyopathy \u2013 Six months follow-up result","name":"articletitle","label":"Article Title"},{"value":"Indian Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ihj.2016.03.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Cardiological Society of India. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}